Products

Dapptize

Uses AI

Build & deploy dApps — no code required

dapptize.io Software Development / Blockchain Development

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Unknown
Freemium model, plan pricing not identified yet
Creators
Lakmal M.
No social account linked
Launched
2y ago
2024-10-08 · Est.

Traffic

Monthly visitsData through Oct 2026

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Product HuntLaunch

    Turn Your Ideas into Web3 Realities, No Code Required!

    Oct 8, 2024 · 2y agoLaunch page

MCP Server & Agent Ecosystem

GitHub · MCP / Skill

Traffic sources

Oct 2026

Traffic breakdown

Channels

No data yet

Countries

No data yet

Search

Domain authority —Domain registered 2026-06-18

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

Starter
Free
Single testnet project
Pro
Unknown
Unlimited projects
Enterprise
Contact sales

Trial: None · Enterprise custom tier · Observed 2026-11-06 · Pricing page

Pages & changes

Tracked since 2024-10-08

Key pages

Weekly snapshots
dapptize.io/ Snapshot 2026-11-06

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much does Dapptize cost?
Starter: Free; Pro: Unknown; Enterprise: Contact sales. Observed 2026-11-06. Check the source for current billing terms, usage limits and taxes.Source
How much website traffic does Dapptize get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Dapptize and what platforms does it support?
Dapptize is catalogued under Blockchain Development: Build & deploy dApps — no code required. Supported platforms: CLI / SDK.

Related products in this category

Software Development / Blockchain Development

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.